middle.news
Immutep’s Efti Combo Delivers Breakthrough Response in Lung Cancer Trial
2:32am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Immutep’s Efti Combo Delivers Breakthrough Response in Lung Cancer Trial
2:32am on Monday 2nd of June, 2025 AEST
Key Points
60.8% overall response rate and 90.2% disease control rate in INSIGHT-003 trial
Strong efficacy in patients with PD-L1 expression below 50%, addressing high unmet need
Triple combination therapy shows improved outcomes versus historical controls
Favourable safety profile with no new adverse signals reported
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE